TGFB1 and glioblastoma: Compared to traditional IL-13Rα2-targeting CAR-T cells, the IL-13Rα2/TGF-β CAR-T cells demonstrate enhanced efficacy against GBM in mouse models and possess the ability to resist and remodel the immunosuppressive microenvironment [149].